This Masters in Cancer Sciences will prepare you for a career in cancer science, whether you aim to pursue a PhD or further medical studies, or seek a career in the health services sector, in the life sciences, biotechnology or pharmaceutical industries. Our programme takes a 'bench to bedside' approach, enabling graduates to work within a multidisciplinary environment of world-leading scientists and cancer-specialists to address the latest challenges in cancer research.
This 13 week core course aims to:
One week of practical training is provided at the start of the course. This course is assessed through a lab notebook, group assessment, critical essay and an exam that focuses on data analysis and interpretation.
In the second semester, you can choose from a range of 3 week optional courses, before taking the core course “Designing a Research Project”.
In this 14 week core course you will:
Note: students must have a minimum of grade C in semesters 1 and 2 in order to proceed to the research project.
The knowledge and transferable skills developed in this programme will be suitable for those contemplating a PhD or further medical studies, those wishing to work in the health services sector, and those interested in working in the life sciences, biotechnology or pharmaceutical industries, including contract research organisations (CROs). This programme is designed for students with undergraduate degrees in the life sciences, scientists working in the pharmaceutical and biotechnology industries, and clinicians and other healthcare professionals.
We invite postgraduate research proposals in a number of disease areas that impact significantly on patient care. We focus on exploring the mechanisms of disease, understanding the ways disease impacts patients’ lives, utilising new diagnostic and therapeutic techniques and developing new treatments.
As a student you will be registered with a University research institute, for many this is the Institute for Cellular Medicine (ICM). You will be supported in your studies through a structured programme of supervision and training via our Faculty of Medical Sciences Graduate School.
We undertake the following areas of research and offer MPhil, PhD and MD supervision in:
Newcastle hosts one of the most comprehensive organ transplant programmes in the world. This clinical expertise has developed in parallel with the applied immunobiology and transplantation research group. We are investigating aspects of the immunology of autoimmune diseases and cancer therapy, in addition to transplant rejection. We have themes to understand the interplay of the inflammatory and anti-inflammatory responses by a variety of pathways, and how these can be manipulated for therapeutic purposes. Further research theme focusses on primary immunodeficiency diseases.
There is strong emphasis on the integration of clinical investigation with basic science. Our research include:
We also research the effects of UVR on the skin including mitochondrial DNA damage as a UV biomarker.
This area emphasises on translational research, linking clinical- and laboratory-based science. Key research include:
Focus is on applied research and aims to underpin future clinical applications. Technology-oriented and demand-driven research is conducted which relates directly to health priority areas such as:
This research is sustained through extensive internal and external collaborations with leading UK and European academic and industrial groups, and has the ultimate goal of deploying next-generation diagnostic and therapeutic systems in the hospital and health-care environment.
There is a number of research programmes into the genetics, immunology and physiology of kidney disease and kidney transplantation. We maintain close links between basic scientists and clinicians with many translational programmes of work, from the laboratory to first-in-man and phase III clinical trials. Specific areas:
We have particular interests in:
Novel non-invasive methodologies using magnetic resonance are developed and applied to clinical research. Our research falls into two categories:
Our studies cover a broad range of topics (including diabetes, dementia, neuroscience, hepatology, cardiovascular, neuromuscular disease, metabolism, and respiratory research projects), but have a common theme of MR technical development and its application to clinical research.
We focus on connective tissue diseases in three, overlapping research programmes. These programmes aim to understand:
This research theme links with other local, national and international centres of excellence and has close integration of basic and clinical researchers and hosts the only immunotherapy centre in the UK.
Genetic approaches to the individualisation of drug therapy, including anticoagulants and anti-cancer drugs, and in the genetics of diverse non-Mendelian diseases, from diabetes to periodontal disease, are a focus. A wide range of knowledge and experience in both genetics and clinical sciences is utilised, with access to high-throughput genotyping platforms.
Our scientists and clinicians use in situ cellular technologies and large-scale gene expression profiling to study the normal and pathophysiological remodelling of vascular and uteroplacental tissues. Novel approaches to cellular interactions have been developed using a unique human tissue resource. Our research themes include:
We also have preclinical molecular biology projects in breast cancer research.
We conduct a broad range of research activities into acute and chronic lung diseases. As well as scientific studies into disease mechanisms, there is particular interest in translational medicine approaches to lung disease, studying human lung tissue and cells to explore potential for new treatments. Our current areas of research include:
Our research projects are concerned with the harmful effects of chemicals, including prescribed drugs, and finding ways to prevent and minimise these effects. We are attempting to measure the effects of fairly small amounts of chemicals, to provide ways of giving early warning of the start of harmful effects. We also study the adverse side-effects of medicines, including how conditions such as liver disease and heart disease can develop in people taking medicines for completely different medical conditions. Our current interests include: environmental chemicals and organophosphate pesticides, warfarin, psychiatric drugs and anti-cancer drugs.
Our new School of Pharmacy has scientists and clinicians working together on all aspects of pharmaceutical sciences and clinical pharmacy.
Do you have a clear and specific interest in cancer, stem cells or developmental biology? Our Master’s programme Cancer, Stem Cells and Developmental Biology combines research in three areas: oncology, molecular developmental biology and genetics. The focus is on molecular and cellular aspects of development and disease, utilising different model systems (mice, zebrafish, C. elegans, organoids and cell lines). The programme will guide you through the mysteries of embryonic growth, stem cells, signalling, gene regulation, evolution, and development as they relate to health and disease.
Given that fundamental developmental processes are so often impacted by disease, an understanding of these processes is vital to the better understanding of disease treatment and prevention. Adult physiology is regulated by developmental genes and mechanisms which, if deregulated, may result in pathological conditions. If you have a specific interest in cancer, stem cells or developmental biology, this Master’s programme is the right choice for you. Cancer, Stem Cells and Developmental Biology offers you international, high ranked research training and education that builds on novel methodology in genomics, proteomics, metabolomics and bioinformatics technology applied to biomedical and developmental systems and processes.
In the Cancer, Stem Cells and Developmental Biology programme you will learn to focus on understanding processes underlying cancer and developmental biology using techniques and applications of post-genomic research, including microarray analysis, next generation sequencing, proteomics, metabolomics and advanced microscopy techniques. You explore research questions concerning embryonic growth, stem cells, signaling pathways, gene regulation, evolution and development in relation to health and disease using various model systems. As a Master’s student you will take theory courses and seminars, as well as master classes led by renowned specialists in the field. The courses are interactive, and challenge you to further improve your writing and presenting skills.
Compared to most other Master’s programmes in cancer and stem cell biology in the Netherlands, in Utrecht we offer:
As a MSc graduate trained in both fundamental and disease-oriented aspects of biomedical genetics you are in great demand. You’ll be prepared for PhD study in one of the participating or associated groups. Alternatively, leaving after obtaining your MSc degree you will profit from a solid education in molecular genetics, in addition to your specialised knowledge of developmental biology. You’ll find your way to biotechnology, the pharmaceutical industry or education.
The only Master’s specialisation in the Netherlands covering the function of our epigenome, a key factor in regulating gene expression and in a wide range of diseases.
Our skin cells, liver cells and blood cells all contain the same genetic information. Yet these are different types of cells, each performing their own specific tasks. How is this possible? The explanation lies in the epigenome: a heritable, cell-type specific set of chromosomal modifications, which regulates gene expression. Radboud University is specialised in studying the epigenome and is the only university in the Netherlands to offer a Master’s programme in this field of research.
The epigenome consists of small and reversible chemical modifications of the DNA or histone proteins, such as methylation, acetylation and phosphorylation. It changes the spatial structure of DNA, resulting in gene activation or repression. These processes are crucial for our health and also play a role in many diseases, like autoimmune diseases, cancer and neurological disorders. As opposed to modifications of the genome sequence itself, epigenetic modifications are reversible. You can therefore imagine the great potential of drugs that target epigenetic enzymes, so-called epi-drugs.
In this specialisation, you’ll look at a cell as one big and complex system. You’ll study epigenetic mechanisms during development and disease from different angles. This includes studying DNA and RNA by next-generation sequencing (epigenomics) and analysing proteins by mass spectrometry (proteomics). In addition, you‘ll be trained to design computational strategies that allow the integration of these multifaceted, high-throughput data sets into one system.
- Radboud University combines various state-of-the-art technologies – such as quantitative mass spectrometry and next-generation DNA sequencing – with downstream bioinformatics analyses in one department. This is unique in Europe.
- This programme allows you to work with researchers from the Radboud Institute for Molecular Life sciences (RIMLS), one of the leading multidisciplinary research institutes within this field of study worldwide.
- We have close contacts with high-profile medically oriented groups on the Radboud campus and with international institutes (EMBL, Max-Planck, Marie Curie, Cambridge, US-based labs, etc). As a Master’s student, you can choose to perform an internship in one of these related departments.
- Radboud University coordinates BLUEPRINT, a 30 million Euro European project focusing on the epigenomics of leukaemia. Master’s students have the opportunity to participate in this project.
As a Master’s student of Medical Epigenomics you’re trained in using state-of-the art technology in combination with biological software tools to study complete networks in cells in an unbiased manner. For example, you’ll know how to study the effects of drugs in the human body.
When you enter the job market, you’ll have:
- A thorough background of epigenetic mechanisms in health and disease, which is highly relevant in strongly rising field of epi-drug development
- Extensive and partly hands-on experience in state-of-the-art ‘omics’ technologies: next-generation sequencing, quantitative mass spectrometry and single cell technologies;
- Extensive expertise in designing, executing and interpreting scientific experiments in data-driven research;
- The computational skills needed to analyse large ‘omics’ datasets.
With this background, you can become a researcher at a:
- University or research institute;
- Pharmaceutical company, such as Synthon or Johnson & Johnson;
- Food company, like Danone or Unilever;
- Start-up company making use of -omics technology.
Apart from research into genomics and epigenomics, you could also work on topics such as miniaturising workflows, improving experimental devices, the interface between biology and informatics, medicine from a systems approach.
Or you can become a:
- Biological or medical consultant;
- Biology teacher;
- Policy coordinator, regarding genetic or medical issues;
- Patent attorney;
- Clinical research associate;
Each year, the Molecular Biology department (Prof. Henk Stunnenberg, Prof. Michiel Vermeulen) and the Molecular Developmental Biology department (Prof. Gert-Jan Veenstra) at the RIMLS offer between five and ten PhD positions. Of course, many graduates also apply for a PhD position at related departments in the Netherlands, or abroad.
- Systems biology
In the Medical Epigenomics specialisation you won’t zoom in on only one particular gene, protein or signalling pathway. Instead, you’ll regard the cell as one complete system. This comprehensive view allows you to, for example, model the impact of one particular epigenetic mutation on various parts and functions of the cell, or study the effects of a drug in an unbiased manner. One of the challenges of this systems biology approach is the processing and integration of large amounts of data. That’s why you’ll also be trained in computational biology. Once graduated, this will be a great advantage: you’ll be able to bridge the gap between biology, technology and informatics , and thus have a profile that is desperately needed in modern, data-driven biology.
- Multiple OMICS approaches
Studying cells in a systems biology approach means connecting processes at the level of the genome (genomics), epigenome (epigenomics), transcriptome (transcriptomics), proteome (proteomics), etc. In the Medical Epigenomics specialisation, you’ll get acquainted with all these different fields of study.
- Patient and animal samples
Numerous genetic diseases are not caused by genetic mutations, but by epigenetic mutations that influence the structure and function of chromatin. Think of:
- Autoimmune diseases, like rheumatoid arthritis and lupus
- Cancer, in the forms of leukaemia, colon cancer, prostate cancer and cervical cancer
- Neurological disorders, like Rett Syndrome, Alzheimer, Parkinson, Multiple Sclerosis, schizophrenia and autism
We investigate these diseases on a cellular level, focusing on the epigenetic mutations and the impact on various pathways in the cell. You’ll get the chance to participate in that research, and work with embryonic stem cell, patient, Xenopus or zebra fish samples.
See the website http://www.ru.nl/masters/medicalbiology/epigenomics
Our MRes Experimental Cancer Medicine master's course will give nurses, doctors and clinical researchers the skills needed to work in early phase clinical studies.
You will learn how to master experimental cancer through a combination of traditional teaching and hands-on learning, spending a year as a member of the Experimental Cancer Medicine Team at The Christie while also taking four structured taught units.
The taught units will see you learn the details of designing and delivering Phase 1 clinical studies, understanding the pre-clinical data required before a clinical programme can commence, and how to optimise early clinical studies to provide evidence for progressing a promising drug into Phase II/III clinical testing.
Alongside the taught elements, you will be allocated to one or more clinical trials that are being conducted by The Christie experimental cancer medicine team. You will have a named trainer and be exposed to tasks required in the setup, delivery, interpretation and audit of a clinical study.
Nursing and physician students will be expected to participate in patient care, including new and follow-on patient clinics, treatment and care-giving episodes with patients.
For clinical trials coordinators, no direct patient contact is envisaged and duties will involve clinical trial setup, protocol amendments, database setup, data entry, costing and billing for clinical research.
You will be able to choose two aspects of your direct clinical trial research experience to write up for your two research projects in a dissertation format. This will give you the skills and knowledge required to critically report medical, scientific and clinically related sciences for peer review.
The primary purpose of the MRes in Experimental Cancer Medicine is to provide you with the opportunity to work within a premier UK Phase 1 cancer clinical trials unit and, through a mix of taught and experiential learning, master the discipline of Experimental Cancer Medicine.
Extensive practical experience
You will spend most of your time gaining hands-on experience within The Christie's Experimental Cancer Medicine Team.
Meet the course team
Dr Natalie Cook is a Senior Clinical Lecturer in Experimental Cancer Medicine at the University and Honorary Consultant in Medical Oncology at The Christie. She completed a PhD at Cambridge, investigating translational therapeutics and biomarker assay design in pancreatic cancer.
Professor Hughes is Chair of Experimental Cancer Medicine at the University and Strategic Director of the Experimental Cancer Medicine team at The Christie. He is a member of the research strategy group for Manchester Cancer Research Centre. He serves on the Biomarker evaluation review panel for CRUK grant applications.
Professor Hughes was previously Global Vice-President for early clinical development at AstraZeneca, overseeing around 100 Phase 0/1/2 clinical studies. He was previously Global Vice-President for early phase clinical oncology, having been involved in over 200 early phase clinical studies.
Dr Matthew Krebs is a Clinical Senior Lecturer in Experimental Cancer Medicine at the University and Honorary Consultant in Medical Oncology at The Christie.
He has a PhD in circulating biomarkers and postdoctoral experience in single cell and ctDNA molecular profiling. He is Principal Investigator on a portfolio of phase 1 clinical trials and has research interests in clinical development of novel drugs for lung cancer and integration of biomarkers with experimental drug development.
Our course is structured around a 2:1 split between clinical-based research projects and taught elements respectively.
Taught course units will predominantly use lectures and workshops.
For the research projects, teaching and learning will take place through one-to-one mentoring from a member of the Experimental Cancer Medicine team.
The clinical and academic experience of contributors to this course will provide you with an exceptional teaching and learning experience.
You will be assessed through oral presentations, single best answer exams, written reports and dissertation.
For each research project, you will write a dissertation of 10,000 to 15,000 words. Examples of suitable practical projects include the following.
Publication-based/dissertation by publication
Service development/professional report/ report based dissertation
Adapted systematic review (qualitative data)
Full systematic review that includes data collection (quantitative data)
Qualitative or quantitative empirical research
Qualitative secondary data analysis/analysis of existing quantitative data
Quantitative secondary data analysis/analysis of existing qualitative data/theoretical study/narrative review
Teaching will take place within The Christie NHS Foundation Trust , Withington.
Practical support and advice for current students and applicants is available from the Disability Advisory and Support Service. Email: [email protected]
This course is relevant to physician, nursing and clinical research students who are considering a career in Phase 1 clinical studies.
The course provides a theoretical and experiential learning experience and offers a foundation for roles within other experimental cancer medicine centres within the UK and EU, as well as careers in academia, the pharmaceutical industry, clinical trials management and medicine.
The MRes is ideal for high-calibre graduates and professionals wishing to undertake directly channelled research training in the clinical and medical oncology field.
The Cancer MSc reflects the depth and breadth of research interests, from basic science to translational medicine, within the UCL Cancer Institute. The programme, taught by research scientists and academic clinicians, provides students with an in-depth look at the biology behind the disease processes which lead to cancer.
This programme offers a foundation in understanding cancer as a disease process and its associated therapies. Students learn about the approaches taken to predict, detect, monitor and treat cancer, alongside the cutting-edge research methods and techniques used to advance our understanding of this disease and design better treatment strategies.
Students undertake modules to the value of 180 credits.
The programme consists of two core modules (60 credits), four specialist modules (60 credits) and a research project (60 credits).
A Postgraduate Diploma (120 credits, full-time nine months) is offered.
A Postgraduate Certificate (60 credits, full-time 12 weeks) is offered.
All MSc students undertake a laboratory project, clinical trials project or systems biology/informatics project, which culminates in a 10,000–12,000 word dissertation and an oral research presentation.
Teaching and learning
Students develop their knowledge and understanding of cancer through lectures, self-study, database mining, wet-lab based practicals, clinical trial evaluations, laboratory training, assigned reading and self-learning. Each taught module is assessed by an unseen written examination and/or coursework. The research project is assessed by the dissertation (75%) and oral presentation (25%).
Further information on modules and degree structure is available on the department website: Cancer MSc
The knowledge and skills developed will be suitable for those in an industrial or healthcare setting, as well as those individuals contemplating a PhD or medical studies in cancer.
Skills include critical evaluation of scientific literature, experimental planning and design interpretation of data and results, presentation/public speaking skills, time management, working with a team, working independently and writing for various audiences.
UCL is one of Europe's largest and most productive centres of biomedical science, with an international reputation for leading basic, translational and clinical cancer research.
The UCL Cancer Institute brings together scientists from various disciplines to synergise multidisciplinary research into cancer, whose particular areas of expertise include: the biology of leukaemia, the infectious causes of cancer, the design of drugs that interact with DNA, antibody-directed therapies, the molecular pathology of cancer, signalling pathways in cancer, epigenetic changes in cancer, gene therapy, cancer stem cell biology, early phase clinical trials, and national and international clinical trials in solid tumours and blood cancers.
The Research Excellence Framework, or REF, is the system for assessing the quality of research in UK higher education institutions. The 2014 REF was carried out by the UK's higher education funding bodies, and the results used to allocate research funding from 2015/16.
The following REF score was awarded to the department: Cancer Institute
80% rated 4* (‘world-leading’) or 3* (‘internationally excellent’)
Learn more about the scope of UCL's research, and browse case studies, on our Research Impact website.
Whether you are a new graduate or already employed and seeking to further your career prospects, this course offers a solid career development path. You can also choose this course if you wish to pursue research in biotechnology at PhD level.
Biotechnology is the application of biological processes and is underpinned by • cell biology • molecular biology • bioinformatics • structural biology. It encompasses a wide range of technologies for modifying living organisms or their products according to human needs.
Applications of biotechnology span medicine, technology and engineering.
Important biotechnological advances including
The course is led by academics who are actively involved in biotechnology research and its application to the manipulation of proteins, DNA, mammalian cells and plants. Staff also have expertise in the use of nanoparticles in drug delivery and the manipulation of microbes in industrial and environmental biotechnology.
You are supported throughout your studies by an academic advisor who will help you develop your study and personal skills.
What is biotechnology
Biotechnology is the basis for the production of current leading biopharmaceuticals and has already provided us with the 'clot-busting' drug, tissue plasminogen activator for the treatment of thrombosis and myocardial infarction. It also holds the promise of new treatments for neurodegeneration and cancer through recombinant antibodies.
Genetically modified plants have improved crop yields and are able to grow in a changing environment. Manipulation of cellular organisms through gene editing methods have also yielded a greater understanding of many disease states and have allowed us to understand how life itself functions.
You begin your studies focusing on the fundamentals of advanced cell biology and molecular biology before specialising in both molecular and plant biotechnology. Practical skills are developed throughout the course and you gain experience in molecular biology techniques such as PCR and sub cloning alongside tissue culture.
Core to the program is the practical module where you gain experience in a range of techniques used in the determination of transcription and translational levels, for example.
All practicals are supported by experienced academic staff, skilled in the latest biotechnological techniques.
Research and statistical skills are developed throughout the program. Towards the end of the program you apply your skills on a two month research project into a current biotechnological application. Employability skills are developed throughout the course in two modules.
The masters (MSc) award is achieved by successfully completing 180 credits.
The postgraduate certificate (PgCert) is achieved by successfully completing 60 credits.
The postgraduate diploma (PgDip) is achieved by successfully completing 120 credits.
Optional modules :
As students progress through the course they are exposed to a wide range of teaching and learning activities. The assessment strategy of the postgraduate course considers diverse assessment methods. Some modules offer dedicated formative feedback to aid skills development with assessments going through several rounds of formative tutor and peer feedback. Summative assessment methods are diverse, with examinations present in theory-based modules to test independent knowledge and data analysis. Several modules are entirely coursework-based, with a portfolio of skills such laboratory practical's and research proposals generated throughout the course forming the summative tasks. In all cases, the assessment criteria for all assessed assignments are made available to student prior to submission.
The course is suitable for people wishing to develop their knowledge of molecular and cell biotechnology and its application to solving health and industrial problems.
You can find career opportunities in areas such as
Students on this course have gone on to roles including experimental officers in contract research, research and development in scientists, diagnostics specialists and applications specialists. Many of our graduates also go on to study for PhDs and continue as academic lecturers.